CRISPR/Cas9の世界市場見通し2022:細胞株エンジニアリング、遺伝子工学、CRISPRプラスミド、遺伝子ライブラリー、ヒト幹細胞、遺伝子組換え(GM)生物/作物

RNCOSが発行した調査報告書(DATA1122055)
◆英語タイトル:Global CRISPR/Cas9 Market Outlook 2022
◆商品コード:DATA1122055
◆発行会社(リサーチ会社):RNCOS
◆発行日:2016年10月
◆ページ数:60
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:バイオ
◆販売価格オプション(消費税別)
Single UserUSD1,200 ⇒換算¥135,600見積依頼/購入/質問フォーム
Multi UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はRNCOS社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。RNCOS社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートはCRISPR/Cas9の世界市場について調査・分析し、CRISPR/Cas9の世界市場規模、CRISPR/Cas9の世界市場動向、関連企業分析などを含め以下の構成でお届けします。1. アナリストの見解
2. 調査方法
3. CRISPR/Cas9ゲノム編集の概要
4. 市場動向
5. CRISPR/Cas9世界市場見通し2022
6. 用途別CRISPR/Cas9市場
7. 需要先別CRISPR/Cas9市場
8. 地域別CRISPR/Cas9市場
9. M&A動向
10. 会社概要
【レポートの概要】

The advent of CRISPR/Cas9 has revolutionized the Genome Editing Industry. This technique is allowing a previously unattainable level of genomic targeting with greater efficiency and simplicity. Due to this ability, the share of CRISPR/Cas9 is incessantly increasing in the Genome Editing Industry. It is anticipated that the global CRISPR/Cas9 market will cross US$ 1.5 Billion by 2022. The growth of the market is likely to be driven by expanding drug discovery applications and increasing research related activities for exploring CRISPR/Cas9 therapeutic applications.

The report, “Global CRISPR/Cas9 Market Outlook 2022”, provides an insight into the current and future prospective of this market. This report covers the major opportunities in this area, and drivers that have impact on the market. The report also discusses some of the challenges currently faced by the market.

The major application areas of CRISPR/Cas9 include cell line engineering, genetic engineering, CRISPR plasmid development, human stem cells, gene library development and producing GM organisms or crops. Cell Line Engineering is the largest area of application of CRISPR/Cas9, followed by Genetic Engineering. This large share can be attributed to extensibility and multiplexity of CRISPR/Cas9 in modifying the multiple sites within the mammalian genome. The genetic engineering market employing CRISPR/Cas9 is expected to witness the highest growth in 2016-2022. This growth is likely to be driven by reduction of evolutionary time in comparison to previous gene editing tools, such as Zinc Finger Nucleases (ZFNs) and Transcription Activator-Like Effector Nucleases (TALENs).

Moreover, the report also contains the market share of major regions, including North America, Europe, Asia Pacific, and the Rest of the World. North America holds the largest market share, while Asia Pacific is expected to witness highest growth in the coming years, i.e. 2016-2022. The major reasons for the high growth are the ongoing researches in China and Japan, which is expanding CRISPR applications to developmental biology. North America and Europe are expected to grow at a modest rate due to launch of new and innovative products in these market. The report also provides market share for the rest of the world which includes regions such as Africa, Latin America, Argentina, etc.

The last segment of the report is entirely devoted to profiling leading companies of the CRISPR/Cas9 industry, including some major players like Thermo Fisher Scientific, Lonza, Agilent Technologies, GenScript, Editas Medicine, Horizon Discovery, etc. This segment provides access to the financials, product portfolio, and recent developments of these companies. This segment also discusses the strengths and weaknesses of key players in this industry. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global CRISPR/Cas9 market.

【レポートの目次】

1. Analyst View
2. Research Methodology
3. Introduction to CRISPR/Cas9 Genome Editing
4. Market Dynamics
4.1 Market Drivers
4.1.1 Expanding Drug Discovery Market
4.1.2 Surging Demand for Synthetic Genes
4.1.3 Rising Prevalence of Genetic Disorders
4.1.4 Increasing Investments
4.2 Market Challenges
4.2.1 Ethical Issues Concerning Misuse of CRISPR Gene Editing Tool
4.2.2 Presence of Alternative Gene Editing Tools
4.3 Market Opportunities
4.3.1 Increasing Usage of CRISPR Gene Editing for Gene Surgery
4.3.2 Enhancing Plant Immunity with CRISPR/Cas9
4.3.3 Emerging Contract Research Market for CRISPR/Cas9
5. Global CRISPR/Cas9 Market Outlook to 2022
6. CRISPR/Cas9 Market by Application
6.1 Cell Line Engineering
6.2 Genetic Engineering
6.3 CRISPR Plasmid
6.4 Gene Library
6.5 Human Stem Cells
6.6 Genetically Modified (GM) Organisms/Crops
7. CRISPR/Cas9 Market by End User
7.1 Academic & Research Institutes
7.2 Pharma/Biotech Companies
7.3 Others
8. CRISPR/Cas9 Market by Geography
8.1 North America
8.2 Europe
8.3 Asia Pacific
8.4 Rest of the World (RoW)
9. Mergers and Collaborations
10. Company Profiles
10.1 GE Healthcare
10.2 Thermo Fisher Scientific, Inc.
10.3 Agilent Technologies, Inc.
10.4 Lonza
10.5 GenScript
10.6 Horizon Discovery Group plc.
10.7 Editas Medicine, Inc.
10.8 CRISPR Therapeutics
10.9 Caribou Biosciences, Inc.
10.10 Intellia Therapeutics, Inc.
10.11 Integrated DNA Technologies
10.12 OriGene Technologies, Inc.
10.13 Transposagen Biopharmaceuticals, Inc.
10.14 New England Biolabs Inc.

List of Figures:

Figure 5-1: Global – CRISPR/Cas9 Market (Million US$), 2016-2022
Figure 6-1: Global – CRISPR/Cas9 Market by Application (%), 2016
Figure 7-1: Global – CRISPR/Cas9 Market by End User (%), 2016
Figure 8-1: Global – CRISPR/Cas9 Market by Geography (%), 2016
Figure 10-1: GE Healthcare – Revenue Breakup by Business Segments (%), 2015
Figure 10-2: GE Healthcare – Revenue Breakup by Geography (%), 2015
Figure 10-3: Thermo Fisher Scientific, Inc. – Revenue Breakup by Business Segments (%), 2015
Figure 10-4: Thermo Fisher Scientific, Inc. – Revenue Breakup by Geography (%), 2015
Figure 10-5: Agilent Technologies, Inc. – Revenue Breakup by Business Segments (%), 2015
Figure 10-6: Agilent Technologies, Inc. – Revenue Breakup by Product Category (%), 2015
Figure 10-7: Agilent Technologies, Inc. – Revenue Breakup by Geography (%), 2015
Figure 10-8: Lonza – Sales Breakup by Business Segments (%), 2015
Figure 10-9: GenScript – Revenue Breakup by Business Segments (%), 2015
Figure 10-10: GenScript – Revenue Breakup by Geography (%), 2015
Figure 10-11: Horizon Discovery Group plc, – Revenue Breakup by Business Segments (%), 2015
Figure 10-12: Horizon Discovery Group plc, – Revenue Breakup by Geography (%), 2015

List of Tables:

Table 10-1: GE Healthcare – Product Portfolio
Table 10-2: GE Healthcare – Key Financials (Million US$), 2013-2015
Table 10-3: Thermo Fisher Scientific, Inc. – Product Portfolio
Table 10-4: Thermo Fisher Scientific, Inc. – Key Financials (Million US$), 2013-2015
Table 10-5: Agilent Technologies, Inc. – Product Portfolio
Table 10-6: Agilent Technologies, Inc. – Key Financials (Million US$), 2013-2015
Table 10-7: Lonza – Technology Portfolio
Table 10-8: Lonza – Key Financials (Million US$), 2013-2015
Table 10-9: GenScript – Product & Technology Portfolio
Table 10-10: GenScript – Key Financials (Million US$), 2013-2015
Table 10-11: Horizon Discovery Group plc, – Product & Service Portfolio
Table 10-12: Horizon Discovery Group plc, – Key Financials (Million US$), 2013-2015
Table 10-13: Editas Medicine, Inc. – Product Pipeline
Table 10-14: Editas Medicine, Inc. – Key Financials (Million US$), 2013-2015
Table 10-15: CRISPR Therapeutics – Product Portfolio
Table 10-16: CRISPR Therapeutics – Product Pipeline
Table 10-17: Caribou Biosciences, Inc. – Product Portfolio
Table 10-18: Intellia Therapeutics – Product Portfolio
Table 10-19: Intellia Therapeutics – Product Pipeline
Table 10-20: Integrated DNA Technologies, Inc. – Product Portfolio
Table 10-21: OriGene Technologies, Inc. – Product Portfolio
Table 10-22: Transposagen Biopharmaceuticals, Inc. – Product Portfolio
Table 10-23: New England Biolabs Inc. – Product Portfolio



【レポートのキーワード】

CRISPR/Cas9、細胞株エンジニアリング、遺伝子工学、CRISPRプラスミド、遺伝子ライブラリー、ヒト幹細胞、遺伝子組換え(GM)生物、遺伝子組換え(GM)作物

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ CRISPR/Cas9の世界市場見通し2022:細胞株エンジニアリング、遺伝子工学、CRISPRプラスミド、遺伝子ライブラリー、ヒト幹細胞、遺伝子組換え(GM)生物/作物(Global CRISPR/Cas9 Market Outlook 2022)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆